Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,752 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Major Depressive Disorders Clear all
Completed Phase 2 Interventional Results available

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

NCT02498392
View directory record Official record
Conditions
Depressive Disorder, Anxiety
Interventions
JNJ-42165279, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Costa Mesa, California • Oceanside, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence

NCT00377299
View directory record Official record
Conditions
Amphetamine Abuse, Amphetamine Dependence, Bipolar Disorder, Major Depressive Disorder
Interventions
Citicoline, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 25, 2026, 11:27 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Schizoaffective Disorder Using Mifepristone

NCT00725270
View directory record Official record
Conditions
Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
Interventions
Mifepristone, Placebo Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Phase 3 Interventional

Study of Duloxetine in Elderly Patients With Major Depressive Disorder

NCT00062673
View directory record Official record
Conditions
Depression, Cognition
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Middleton, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 21, 2007 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Not applicable Interventional Results available

Electroconvulsive Therapy Amplitude Titration

NCT04621786
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface
Device
Lead sponsor
University of New Mexico
Other
Eligibility
50 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 25, 2026, 11:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heart Disease Risk Factors in Major Depression

NCT00001969
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Phase 4 Interventional Results available

Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder

NCT01473394
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Dose-matched placebo, Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Beverly Hills, California • Encino, California • New Port Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

NCT03357796
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Results available

Closed-loop Optimized rTMS for Depression

NCT04142320
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Neuronavigated rTMS, sham rTMS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 11:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Brain Responses to Facial Expressions in Major Depressive Disorder

NCT00071123
View directory record Official record
Conditions
Current Major Depressive Disorder, Healthy, Remitted Major Depressive Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Not applicable Interventional

Comparing Thinking Skills for Work (TSW)Home Practice Program With Traditional TSW Program

NCT03005574
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
TSW-HP, TSW-T
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Phase 2 Interventional Results available

Rapid Antidepressant Effects of Yohimbine in Major Depression

NCT00078715
View directory record Official record
Conditions
Depression, Involutional, Major Depresssion
Interventions
Yohimbine hydrochloride, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 25, 2026, 11:27 PM EDT
Recruiting Phase 2 Interventional

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

NCT07494305
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
LB-102, Placebo
Drug · Other
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Phase 3 Interventional

Clinical Trial of Memantine for Major Depression

NCT00040261
View directory record Official record
Conditions
Depression
Interventions
Memantine HCL
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Not applicable Interventional

Clinical Outcomes of a Digital Mental Health Intervention for Moderate/Severe Depression and Anxiety

NCT07081061
View directory record Official record
Conditions
Depression, Anxiety, Mental Health Issue, Mental Health Wellness 2
Interventions
BetterHelp
Other
Lead sponsor
Teladoc Health
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 25, 2026, 11:27 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

MRS and Medication Response: A Pilot Study

NCT03254342
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild, Major Depression Moderate, Major Depression Severe
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Not applicable Interventional

Frequency and E-field Enhancement of ITBS for Depression (FREED)

NCT06003309
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS, Transcranial Magnetic Stimulation (TMS) - targeted-iTBS, Transcranial Magnetic Stimulation (TMS) - Standard-iTBS
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ketamine in the Treatment of Depression

NCT01558063
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Saline, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 25, 2026, 11:27 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder

NCT00659347
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DOV 21, 947, Placebo
Drug
Lead sponsor
DOV Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
10
States / cities
Norwich, Connecticut • Springfield, Massachusetts • Cherry Hill, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2008 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

NCT00101452
View directory record Official record
Conditions
Depression
Interventions
S-adenosyl-l-methionine, Escitalopram, Placebo
Drug
Lead sponsor
Maurizio Fava, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Not applicable Interventional Results available

Increasing Use of Mental Health Services

NCT00605358
View directory record Official record
Conditions
Major Depression
Interventions
Open Door intervention
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 90 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 25, 2026, 11:27 PM EDT
Completed Phase 1 Interventional

Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use

NCT06920238
View directory record Official record
Conditions
Cannabis Use Disorder, Anxiety, Depression, Anxiety, Depression - Major Depressive Disorder
Interventions
Therabot-CALM
Device
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 25, 2026, 11:27 PM EDT
Not listed Not applicable Interventional

Self-guided Treatment for Depression

NCT06028984
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Intervention app, Control app
Device · Other
Lead sponsor
Big Health Inc.
Industry
Eligibility
13 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 25, 2026, 11:27 PM EDT
Terminated Phase 2 Interventional Results available

6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

NCT01145755
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD2066, Placebo, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
13
States / cities
Garden Grove, California • San Diego, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 25, 2026, 11:27 PM EDT